CSIMarket
 
Pacira Biosciences inc   (NASDAQ: PCRX)
Other Ticker:  
 
 
Price: $23.3450 $0.04 0.150%
Day's High: $23.65 Week Perf: 5.92 %
Day's Low: $ 22.56 30 Day Perf: -8.24 %
Volume (M): 162 52 Wk High: $ 31.67
Volume (M$): $ 3,793 52 Wk Avg: $21.86
Open: $23.25 52 Wk Low: $11.16



 Market Capitalization (Millions $) 1,081
 Shares Outstanding (Millions) 46
 Employees 503
 Revenues (TTM) (Millions $) 701
 Net Income (TTM) (Millions $) -100
 Cash Flow (TTM) (Millions $) 123
 Capital Exp. (TTM) (Millions $) 11

Pacira Biosciences Inc
Pacira Biosciences Inc. is a specialty pharmaceutical company that focuses on developing and commercializing innovative drug therapies that enhance patient outcomes. The company's portfolio includes best-in-class regional anesthesia and analgesia products, as well as long-acting local anesthetic formulations for postoperative pain management.

The company was founded in 2006 as Pacira Pharmaceuticals, Inc. and is headquartered in Parsippany, New Jersey. It has grown rapidly in recent years, with a strong track record of clinical research and development, as well as a commitment to sustainability and social responsibility.

One of Pacira's flagship products is Exparel, a long-acting, liposome-based local anesthetic that provides up to 72 hours of pain relief following surgery. Exparel has been approved by the FDA for a wide variety of surgical procedures, and is considered a safe and effective alternative to traditional opioid-based pain management strategies.

Pacira's other products include DepoCyt(e), a chemotherapy drug for the treatment of lymphomatous meningitis, and iovera, a non-opioid, non-invasive pain management system that uses cold therapy to block nerve signals and provide pain relief.

In addition to its pharmaceutical products, Pacira is also committed to sustainability and social responsibility. The company has implemented several initiatives aimed at reducing its environmental impact, including a zero-waste program and efforts to minimize energy and water usage. It also supports a range of philanthropic causes, including organizations focused on cancer research and patient advocacy.

Overall, Pacira Biosciences Inc. is a cutting-edge pharmaceutical company that is pioneering innovative drug therapies for pain management and making significant progress in achieving sustainable and socially responsible business practices.


   Company Address: 5401 West Kennedy Boulevard Tampa 33609 FL
   Company Phone Number: 553-6680   Stock Exchange / Ticker: NASDAQ PCRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMRX   -2.36%    
BHC        0.57% 
JNJ        0.83% 
PBYI   -5.54%    
TEVA   -1.17%    
VTRS        2.06% 
• View Complete Report
   



Merger and Acquisition

Pacira Biosciences Expands Vision as Innovative Biopharmaceutical Leader with Breakthrough Local-Delivery Platform Amidst Legal Challenges

Published Thu, Feb 27 2025 9:00 PM UTC

Breaking News Pacira Biosciences Advances to Become Innovative Biopharmaceutical OrganizationIn a significant development for the biopharmaceutical landscape, Pacira Biosciences Inc. (NASDAQ: PCRX) has unveiled its ambitious plan to evolve into a cutting-edge biopharmaceutical organization. The announcement highlights the company?s latest advancement: a novel, high-capacity ...

Announcement

Pacira BioSciences Faces Securities Lawsuit as Financial Decline Sparks Shareholder Legal Action,

Published Fri, Feb 21 2025 8:09 PM UTC

Shareholders Alerted as Levi & Korsinsky Announces Lead Plaintiff Deadline in Pacira BioSciences Lawsuit New York, February 21, 2025 Levi & Korsinsky, LLP has issued a notification to investors in Pacira BioSciences, Inc. (Pacira or the Company), regarding a class action securities lawsuit currently in motion. Shareholders are reminded of the upcoming deadline of March 1...

Shares

Pacira BioSciences Announces Inducement Grants: Assessing the Implications for Future Growth

Published Thu, Feb 6 2025 1:00 PM UTC

In a recent press release dated February 6, 2025, Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in non-opioid pain management solutions, shared an important update regarding its human resources and corporate strategy. The company announced the issuance of inducement awards to 15 newly hired employees as part of its strategy to attract and retain top-tier talent.Understan...

Management Announcement

Pacira Biosciences Sets Ambitious Five-Year Goals and Reports Strong Preliminary Revenue, Spotlighting Promising Developments in Osteoarthritis Treatment with PCRX-201

Published Fri, Jan 10 2025 1:01 PM UTC

In a strategic move signaling its commitment to innovation and growth, Pacira Biosciences has announced new five-year objectives designed to expedite its transformation into a leading biopharmaceutical entity. With a robust preliminary unaudited revenue projection for 2024 at $701.0 million, the company is poised to leverage this financial momentum to enhance its research an...

Clinical Study

Evaluating Long-Term Safety and Efficacy of PCRX-201 for Osteoarthritis Insights from Pacira Biosciences

Published Thu, Nov 14 2024 3:05 PM UTC

Abstract: This article aims to synthesize findings from recent data presented by Pacira Biosciences at the ACR Convergence annual meeting regarding the long-term safety and efficacy of their investigational product, PCRX-201, for moderate to severe osteoarthritis of the knee. It will provide an overview of the product?s clinical profile and market context based on available ...







Pacira Biosciences Inc's Segments
EXPAREL    78.31 % of total Revenue
ZILRETTA    16.86 % of total Revenue
iovera    3.35 % of total Revenue
Bupivacaine liposome injectable suspension    0.97 % of total Revenue
Total net product sales    99.5 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com